Ticagrelor

Ticagrelor

File:Ticagrelor structure.svg
Clinical data
Routes of administration	oral
ATC code	none
Identifiers
IUPAC name (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
CAS Number	274693-27-5
PubChem CID	9871419
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C23H28F2N6O4S
Molar mass	522.567 g/mol
3D model (JSmol)	Interactive image
SMILES Fc2ccc(cc2F)C3CC3Nc5nc(SCCC)nc4c5nnn4C1CC(C(O)C1O)OCCO

WikiDoc Resources for Ticagrelor
Articles
Most recent articles on Ticagrelor Most cited articles on Ticagrelor Review articles on Ticagrelor Articles on Ticagrelor in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ticagrelor Images of Ticagrelor Photos of Ticagrelor Podcasts & MP3s on Ticagrelor Videos on Ticagrelor
Evidence Based Medicine
Cochrane Collaboration on Ticagrelor Bandolier on Ticagrelor TRIP on Ticagrelor
Clinical Trials
Ongoing Trials on Ticagrelor at Clinical Trials.gov Trial results on Ticagrelor Clinical Trials on Ticagrelor at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ticagrelor NICE Guidance on Ticagrelor NHS PRODIGY Guidance FDA on Ticagrelor CDC on Ticagrelor
Books
Books on Ticagrelor
News
Ticagrelor in the news Be alerted to news on Ticagrelor News trends on Ticagrelor
Commentary
Blogs on Ticagrelor
Definitions
Definitions of Ticagrelor
Patient Resources / Community
Patient resources on Ticagrelor Discussion groups on Ticagrelor Patient Handouts on Ticagrelor Directions to Hospitals Treating Ticagrelor Risk calculators and risk factors for Ticagrelor
Healthcare Provider Resources
Symptoms of Ticagrelor Causes & Risk Factors for Ticagrelor Diagnostic studies for Ticagrelor Treatment of Ticagrelor
Continuing Medical Education (CME)
CME Programs on Ticagrelor
International
Ticagrelor en Espanol Ticagrelor en Francais
Business
Ticagrelor in the Marketplace Patents on Ticagrelor
Experimental / Informatics
List of terms related to Ticagrelor

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Ticagrelor (AZD6140) is a platelet aggregation inhibitor produced by AstraZeneca. As of February 2008, a clinical trial (PLATO: Platelet inhibition and patient outcomes) is comparing a combination of ticagrelor plus aspirin to clopidogrel plus aspirin for the prevention of thromboembolism.

Method of action

Like clopidogrel and ticlopidine, ticagrelor blocks ADP receptors of subtype P2Y₁₂. In contrast to the other antiplatelet drugs, the blockage is reversible. Moreover, it does not need hepatic activation, which could reduce the risk of drug interactions.

PLATO trial

This trial, recently published in New England Journal of Medicine, has confirmed the superiority of ticagrelor over clopidogel in patients with acute coronary syndromes.